Navidea (NAVB) Receives a Buy from Maxim Group

By Austin Angelo

Maxim Group analyst Jason McCarthy maintained a Buy rating on Navidea (NAVBResearch Report) yesterday and set a price target of $7.00. The company’s shares closed last Friday at $3.27.

According to TipRanks.com, McCarthy is a 5-star analyst with an average return of 29.5% and a 51.1% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Lineage Cell Therapeutics, and Vertex Pharmaceuticals.

Navidea has an analyst consensus of Moderate Buy, with a price target consensus of $6.50.

See today’s analyst top recommended stocks >>

The company has a one-year high of $5.36 and a one-year low of $0.50. Currently, Navidea has an average volume of 1.89M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Navidea Biopharmaceuticals, Inc. engages in the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through the following segments: Diagnostics, Therapeutics, and Corporate. The company was founded in 1983 and is headquartered in Dublin, OH.